Menu Search
Equities

Intelligent Bio Solutions Inc

12Q0:MUN

Intelligent Bio Solutions Inc

Actions
  • Price (EUR)4.92
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-85.04%
  • Beta--
Data delayed at least 15 minutes, as of Feb 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Intelligent Bio Solutions Inc. is a life sciences company. The Company is engaged in developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It operates through two segments, namely Commercially available Intelligent Fingerprinting Products (IFPG) and Development Stage Saliva Glucose Biosensor Platform (SGBP). Its product portfolio includes a portable drug screening system that works by analyzing fingerprint sweat using a one-time cartridge and portable handheld reader and also includes a development stage range of biosensor- based Point of Care diagnostic tests (POCT) that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology. Its product candidate is the Saliva Glucose Biosensor (SGB), a POCT expected to substitute the finger pricking invasive blood glucose monitoring for diabetic patients. Its Biosensor Platform helps to detect multiple biological analytes.

  • Revenue in USD (TTM)2.83m
  • Net income in USD-10.03m
  • Incorporated2016
  • Employees17.00
  • Location
    Intelligent Bio Solutions Inc142 West 57Th St Fl11NEW YORK 10019United StatesUSA
  • Phone+1 (646) 233-6971
  • Fax+1 (302) 575-1642
  • Websitehttps://ibs.inc/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.